Association between COVID-19 Primary Vaccination and Severe Disease Caused by SARS-CoV-2 Delta Variant among Hospitalized Patients: A Belgian Retrospective Cohort Study

Robalo, Queeny; Mot, Laurane De; Vandromme, Mathil; Goethem, Nina Van; Gabrio, Andrea; Chung, Pui Yan Jenny; Meurisse, Marjan; Catteau, Lucy; Thijs, Carel; Blot, Koen

doi:10.3390/vaccines11010014

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the influence of COVID-19 vaccinations on ARDS is critical. Fortunately, primary vaccination against SARS-CoV-2 infection prevents the development of ARDS and death in patients hospitalized after COVID-19 infection (Robalo et al, 2023). Similarly, in-hospital mortality could also been reduced in mechanically ventilated COVID-19 induced ARDS patients after the full vaccination (Siempos et al, 2022).…”

Section: Impact Of Covid-19 Vaccines In Acute Respiratory Distress Sy...mentioning

confidence: 99%

Molecular basis of COVID-19, ARDS and COVID-19-associated ARDS: Diagnosis pathogenesis and therapeutic strategies

SRIRAMAMOORTHI,

GOPAL,

MURALIDAR

et al. 2023

BIOCELL

View full text Add to dashboard Cite

The novel coronavirus pneumonia (COVID-19) is spreading worldwide and threatening people greatly. The routes by which SARS-CoV-2 causes lung injury have grown to be a major concern in the scientific community since patients with new Coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2) have a high likelihood of developing acute respiratory distress syndrome (ARDS) in severe cases. The mortality rate of COVID-19 has increased over the period due to rapid spread, and it becomes crucial to understand the disease epidemiology, pathogenic mechanisms, and suitable treatment strategies. ARDS is a respiratory disorder and is one of the clinical manifestations observed in patients with severe COVID-19. In this scenario, it is important to address this problem to develop suitable treatment strategies. This review attempts to present the prevalence of ARDS in COVID-19 patients and their predictive causes and risk factors, highlighting the contrasting features of COVID-19-induced ARDS with typical ARDS. This review also presents insights into the association between SARS-CoV-2 and lung damage while exploring the potential COVID-19 mechanisms in ARDS from the perspective of the angiotensin-converting enzyme 2 protein, cytokine storm, immune responses, and other signaling pathways. The review also discusses the diagnosis strategies, pathogenesis, risk factors, and treatment options of COVID-19-related ARDS.

show abstract

Section: Impact Of Covid-19 Vaccines In Acute Respiratory Distress Sy...mentioning

confidence: 99%

Molecular basis of COVID-19, ARDS and COVID-19-associated ARDS: Diagnosis pathogenesis and therapeutic strategies

SRIRAMAMOORTHI,

GOPAL,

MURALIDAR

et al. 2023

BIOCELL

View full text Add to dashboard Cite

show abstract

“…A large amount of evidence has indicated that vaccinations are particularly effective in reducing the incidence of severity and mortality among COVID-19 patients [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. To date, more than 200 COVID-19 vaccine candidates are in various stages of development, and more than 50 of these candidates have started clinical trials.…”

Section: Introductionmentioning

confidence: 99%

A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity

Wang

Shi

et al. 2023

Vaccines

View full text Add to dashboard Cite

The association between peptic ulcer disease and the severity of coronavirus disease 2019 (COVID-19) is inconclusive across individual studies. Thus, this study aimed to investigate whether there was a significant association between peptic ulcer disease and COVID-19 severity through a meta-analysis. The electronic databases (Web of Science, Wiley, Springer, EMBASE, Elsevier, Cochrane Library, Scopus and PubMed) were retrieved for all eligible studies. The Stata 11.2 software was used for all statistical analyses. The pooled odds ratio (OR) with a 95% confidence interval (CI) was calculated by a random-effects meta-analysis model. The heterogeneity was evaluated by the inconsistency index (I2) and Cochran’s Q test. Egger’s analysis and Begg’s analysis were conducted to evaluate the publication bias. Meta-regression analysis and subgroup analysis were done to explore the potential source of heterogeneity. Totally, our findings based on confounding variables-adjusted data indicated that there was no significant association between peptic ulcer disease and the higher risk for COVID-19 severity (pooled OR = 1.17, 95% CI: 0.97–1.41) based on 15 eligible studies with 4,533,426 participants. When the subgroup analysis was performed by age (mean or median), there was a significant association between peptic ulcer disease and a higher risk for COVID-19 severity among studies with age ≥ 60 years old (pooled OR = 1.15, 95% CI: 1.01–1.32), but not among studies with age < 60 years old (pooled OR = 1.16, 95% CI: 0.89–1.50). Our meta-analysis showed that there was a significant association between peptic ulcer disease and a higher risk for COVID-19 severity among older patients but not among younger patients.

show abstract

Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review

Bolormaa,

Shim,

Choi

et al. 2024

PHRP

View full text Add to dashboard Cite

Objectives: This study aimed to comprehensively outline the methodological approaches used in published research comparing the vaccine effectiveness (VE) of coronavirus disease 2019 (COVID-19) vaccines.Methods: A systematic search was conducted on June 13, 2024, to identify comparative studies evaluating the effectiveness of mRNA versus non-mRNA and monovalent versus bivalent COVID-19 vaccines. We screened titles, abstracts, and full texts, collecting data on publication year, country, sample size, study population composition, study design, VE estimates, outcomes, and covariates. Studies that reported relative VE (rVE) were analyzed separately from those that did not.Results: We identified 25 articles comparing rVE between mRNA and non-mRNA COVID-19 vaccines, as well as between monovalent and bivalent formulations. Among the studies assessing VE by vaccine type, 126 did not provide rVE estimates. Comparative VE studies frequently employed retrospective cohort designs. Among the definitions of rVE used, the most common were hazard ratio and absolute VE, calculated as (1−odds ratio)×100. Studies were most frequently conducted in the United Kingdom and the United States, and the most common outcome was infection. Most targeted the general population and assessed the VE of mRNA vaccines using the AstraZeneca vaccine as a reference. A small proportion, 7.3% (n=11), did not adjust for any variables. Only 3 studies (2.0%) adjusted for all core confounding variables recommended by the World Health Organization.Conclusion: Few comparative studies of COVID-19 vaccines have incorporated rVE methodologies. Reporting rVE and employing a consistent set of covariates can broaden our understanding of COVID-19 vaccines.

show abstract

Association between COVID-19 Primary Vaccination and Severe Disease Caused by SARS-CoV-2 Delta Variant among Hospitalized Patients: A Belgian Retrospective Cohort Study

Cited by 3 publications

References 36 publications

Molecular basis of COVID-19, ARDS and COVID-19-associated ARDS: Diagnosis pathogenesis and therapeutic strategies

Molecular basis of COVID-19, ARDS and COVID-19-associated ARDS: Diagnosis pathogenesis and therapeutic strategies

A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity

Methodology of comparative studies on the relative effectiveness of COVID-19 vaccines: a systematic review

Contact Info

Product

Resources

About